Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NNMT | P40261 | 1/20 | 0.37 |
| ▸ | HCAR3 | P49019 | 10/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.32 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetone SCHEMBL17732267 | 0.99 | NNMT (0.36) | NNMTHCAR3MAPK1HCAR2KDM4E | |
| SCHEMBL5580002 | 0.96 | NNMT (0.36) | NNMTHCAR3MAPK1HCAR2KDM4E | |
| Hydrochloric Acid SCHEMBL1235153 | 0.95 | NNMT (0.35) | NNMTHCAR3MAPK1HCAR2KDM4E | |
| SCHEMBL23070480 | 0.88 | NNMT (0.41) | NNMTHCAR3MAPK1HCAR2KDM4E | |
| SCHEMBL6756021 | 0.80 | — | — | |
| SCHEMBL1831271 | 0.78 | GAA (0.38) | HCAR3GABRA5L3MBTL1MEN1GAA | |
| Acetone SCHEMBL993035 | 0.78 | KDM4E (0.34) | NNMTHCAR3MAPK1HCAR2KDM4E | |
| Hydrochloric Acid SCHEMBL7910400 | 0.76 | GAA (0.37) | KDM4EMEN1LMNAGAAMAPT | |
| Hydrochloric Acid SCHEMBL7910501 | 0.76 | GAA (0.37) | KDM4EMEN1LMNAGAAMAPT | |
| SCHEMBL6307975 | 0.74 | MAPT (0.40) | L3MBTL1LMNAGAAMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 140 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022221706-A1 | METHODS FOR ANTIBODY IDENTIFICATION AND QUANTIFICATION | SEQTECH DIAGNOSTICS LLC (US) | 2022-10-20 | — | — | WO | claimed |
| EP-2714752-B1 | METHODS FOR COUPLING TARGETING PEPTIDES ONTO RECOMBINANT LYSOSOMAL ENZYMES FOR IMPROVED TREATMENTS OF LYSOSOMAL STORAGE DISEASES | AMICUS THERAPEUTICS INC (US) | 2017-11-22 | — | — | EP | claimed |
| US-8846875-B2 | Preparation and/or purification of oligonucleotide conjugates | SOLULINK, INC. (US) | 2014-09-30 | — | — | US | claimed |
| WO-2014082080-A2 | METHODS FOR COUPLING TARGETING PEPTIDES ONTO RECOMBINANT LYSOSOMAL ENZYMES FOR IMPROVED TREATMENTS OF LYSOSOMAL STORAGE DISEASES | CALLIDUS BIOPHARMA, INC. (US) | 2014-05-30 | — | — | WO | claimed |
| WO-2012166653-A2 | METHODS FOR COUPLING TARGETING PEPTIDES ONTO RECOMBINANT LYSOSOMAL ENZYMES FOR IMPROVED TREATMENTS OF LYSOSOMAL STORAGE DISEASES | CALLIDUS BIOPHARMA, INC. (US) | 2012-12-06 | — | — | WO | claimed |
| US-20060153839-A1 | Production of bispecific molecules using polyethylene glycol linkers | ELUSYS THERAPEUTICS, INC. (US) | 2006-07-13 | — | — | US | claimed |
| EP-1539811-A4 | PRODUCTION OF BISPECIFIC MOLECULES USING POLYETHYLENE GLYCOL LINKERS | ELUSYS THERAPEUTICS INC (US) | 2006-05-24 | — | — | EP | claimed |
| EP-1539811-A2 | PRODUCTION OF BISPECIFIC MOLECULES USING POLYETHYLENE GLYCOL LINKERS | Elusys Therapeutics, Inc. (US) | 2005-06-15 | — | — | EP | claimed |
| WO-2004024889-A2 | PRODUCTION OF BISPECIFIC MOLECULES USING POLYETHYLENE GLYCOL LINKERS | ELUSYS THERAPEUTICS, INC. (US) | 2004-03-25 | — | — | WO | claimed |
| US-12019077-B2 | Macromolecule analysis employing nucleic acid encoding | Encodia, Inc. (US) | 2024-06-25 | — | — | US | disclosed |
| US-12019078-B2 | Macromolecule analysis employing nucleic acid encoding | Encodia, Inc. (US) | 2024-06-25 | — | — | US | disclosed |
| US-20240125792-A1 | KITS FOR ANALYSIS USING NUCLEIC ACID ENCODING AND/OR LABEL | DF PEPTIDE ACQUISITION LLC | 2024-04-18 | — | — | US | disclosed |
| US-11959922-B2 | Macromolecule analysis employing nucleic acid encoding | Encodia, Inc. (US) | 2024-04-16 | — | — | US | disclosed |
| EP-4323517-A2 | COMPOSITIONS CONTAINING NUCLEIC ACID NANOPARTICLES AND PROCESSES RELATED TO ALTERATION OF THEIR PHYSICOCHEMICAL CHARACTERISTICS | Sixfold Bioscience Ltd. (GB) | 2024-02-21 | — | — | EP | disclosed |
| EP-1305327-A2 | TRIPHOSPHATE OLIGONUCLEOTIDE MODIFICATION REAGENTS AND USES THEREOF | Schwartz, David A. (US) | 2003-05-02 | — | — | EP | disclosed |
| US-20030013857-A1 | Hydrazine-based and carbonyl-based bifunctional crosslinking reagents | SOLULINK INCORPORATED | 2003-01-16 | — | — | US | disclosed |
| US-20020146504-A1 | Ternary biomolecule/polymer/surface-based immobilization systems | AUDAX PRIVATE DEBT LLC, AS AGENT | 2002-10-10 | — | — | US | disclosed |
| WO-2002057422-A2 | TERNARY BIOMOLECULE/POLYMER/SURFACE-BASED IMMOBILIZATION SYSTEMS | SCHWARTZ DAVID A (US) | 2002-07-25 | — | — | WO | disclosed |
| WO-2002010432-A2 | TRIPHOSPHATE OLIGONUCLEOTIDE MODIFICATION REAGENTS AND USES THEREOF | SCHWARTZ DAVID A (US) | 2002-02-07 | — | — | WO | disclosed |
| WO-2001070685-A2 | HYDRAZINE-BASED AND CARBONYL-BASED BIFUNCTIONAL CROSSLINKING REAGENTS | SOLULINK, INCORPORATED (US) | 2001-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020146504-A1 | Ternary biomolecule/polymer/surface-based immobilization systems | EPCAM, DNPEP, ANPEP | NNMT 1358/4885HCAR3 467/4885MAPK1 3974/4885 |
| US-20060153839-A1 | Production of bispecific molecules using polyethylene glycol linkers | TNFSF11, TNFSF10, CLTA | NNMT 4318/4885HCAR3 1066/4885MAPK1 2259/4885 |
| US-20030013857-A1 | Hydrazine-based and carbonyl-based bifunctional crosslinking reagents | HLCS, DUOX1, HAO2 | NNMT 607/4885HCAR3 626/4885MAPK1 3810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.